Abstract
Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a "U-shaped" curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.
| Original language | English |
|---|---|
| Pages (from-to) | 727-736 |
| Number of pages | 10 |
| Journal | American Journal of Cardiology |
| Volume | 114 |
| Issue number | 5 |
| DOIs | |
| State | Published - Sep 1 2014 |
Fingerprint
ASJC Scopus subject areas
- Cardiology and Cardiovascular Medicine
Cite this
Optimal Blood Pressure in Patients with Atrial Fibrillation (from the AFFIRM Trial). / Badheka, Apurva O.; Patel, Nileshkumar J.; Grover, Peeyush M.; Shah, Neeraj; Patel, Nilay; Singh, Vikas; Deshmukh, Abhishek J.; Mehta, Kathan; Chothani, Ankit; Savani, Ghanshyambhai T.; Arora, Shilpkumar; Rathod, Ankit; Marzouka, George R.; Lafferty, James; Mehta, Jawahar L.; Mitrani, Raul.
In: American Journal of Cardiology, Vol. 114, No. 5, 01.09.2014, p. 727-736.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Optimal Blood Pressure in Patients with Atrial Fibrillation (from the AFFIRM Trial)
AU - Badheka, Apurva O.
AU - Patel, Nileshkumar J.
AU - Grover, Peeyush M.
AU - Shah, Neeraj
AU - Patel, Nilay
AU - Singh, Vikas
AU - Deshmukh, Abhishek J.
AU - Mehta, Kathan
AU - Chothani, Ankit
AU - Savani, Ghanshyambhai T.
AU - Arora, Shilpkumar
AU - Rathod, Ankit
AU - Marzouka, George R.
AU - Lafferty, James
AU - Mehta, Jawahar L.
AU - Mitrani, Raul
PY - 2014/9/1
Y1 - 2014/9/1
N2 - Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a "U-shaped" curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.
AB - Many medications used to treat atrial fibrillation (AF) also reduce blood pressure (BP). The relation between BP and mortality is unclear in patients with AF. We performed a post hoc analysis of 3,947 participants from the Atrial Fibrillation Follow-Up Investigation of Rhythm Management trial. Systolic blood pressure (SBP) and diastolic blood pressure (DBP) at baseline and follow-up were categorized by 10-mm Hg increments. The end points were all-cause mortality (ACM) and secondary outcome (combination of ACM, ventricular tachycardia and/or fibrillation, pulseless electrical activity, significant bradycardia, stroke, major bleeding, myocardial infarction, and pulmonary embolism). SBP and DBP followed a "U-shaped" curve with respect to primary and secondary outcomes after multivariate analysis. A nonlinear Cox proportional hazards model showed that the incidence of ACM was lowest at 140/78 mm Hg. Subgroup analyses revealed similar U-shaped curves. There was an increased ACM observed with BP <110/60 mm Hg (hazard ratio 2.4, p <0.01, respectively, for SBP and DBP). In conclusion, in patients with AF, U-shaped relation existed between BP and ACM. These data suggest that the optimal BP target in patients with AF may be greater than the general population and that pharmacologic therapy to treat AF may be associated with ACM or adverse events if BP is reduced to <110/60 mm Hg.
UR - http://www.scopus.com/inward/record.url?scp=84908375946&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84908375946&partnerID=8YFLogxK
U2 - 10.1016/j.amjcard.2014.06.002
DO - 10.1016/j.amjcard.2014.06.002
M3 - Article
VL - 114
SP - 727
EP - 736
JO - American Journal of Cardiology
JF - American Journal of Cardiology
SN - 0002-9149
IS - 5
ER -